ProPhase Labs Inc - Asset Resilience Ratio
ProPhase Labs Inc (PRPH) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read PRPH total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how ProPhase Labs Inc's Asset Resilience Ratio has changed over time. See shareholders equity of ProPhase Labs Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ProPhase Labs Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see PRPH market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.00K | 0.0% |
| Total Liquid Assets | $2.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: ProPhase Labs Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ProPhase Labs Inc Industry Peers by Asset Resilience Ratio
Compare ProPhase Labs Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for ProPhase Labs Inc (2011–2024)
The table below shows the annual Asset Resilience Ratio data for ProPhase Labs Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | $0.00 | $63.20 Million | -- |
| 2023-12-31 | 3.40% | $3.13 Million | $91.93 Million | -6.10pp |
| 2022-12-31 | 9.50% | $8.33 Million | $87.65 Million | -0.41pp |
| 2021-12-31 | 9.92% | $8.86 Million | $89.30 Million | +4.70pp |
| 2020-12-31 | 5.22% | $1.64 Million | $31.41 Million | -2.33pp |
| 2019-12-31 | 7.54% | $926.00K | $12.27 Million | -24.70pp |
| 2018-12-31 | 32.25% | $6.69 Million | $20.74 Million | -22.68pp |
| 2017-12-31 | 54.93% | $18.77 Million | $34.16 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $12.80 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $14.83 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $16.06 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $17.42 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $16.66 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $19.08 Million | -- |
About ProPhase Labs Inc
ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of dietary supplements under the TK supplements, including Legendz XL, a male sexual enhancement; and Triple Edge XL, an energy and stamina booster. It also develops BE-Smart … Read more